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Efflux pumps in Mycobacterium tuberculosis:  
What is their role in multi-drug resistance? 
 
EFFLUX PUMPS 
Mycobacterium tuberculosis infection remains a major cause of 
morbidity and mortality in large parts of the world and is 
considered to be one of the most important global health 
problems. Despite the use of vaccine and effective antibiotics, in 
2012, an estimated 8.6 million people developed TB and 1.3 
million died from the disease (including 320 000 deaths among 
HIV-positive people). (WHO,2013) 
 
Rifampicin and isoniazid are the two main drugs used in current first-line anti-TB chemotherapy. Multi-drug resistant 
tuberculosis (MDR-TB) is caused when M.tuberculosis is resistant, at least  to these both drugs. 
Antibiotic tolerance can be defined as the ability of bacteria to stop growing in the presence of an antibiotic, while still 
surviving to resume growth once the antibiotic has been removed. Even though antibiotic resistance is attributed to gene 
mutations in genes involved in cell wall biosynthesis, some strains have appeared with no mutations but the presence of 
efflux pumps, considered to be the mechanism to extrude the drugs. [1] 
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In a strain of M.bovis BCG, used as a model for the analysis, when exposed to antibiotics, 
disruption of the Tap transporter (KOTap cells) or its overexpression, altered the strain 
susceptibility. Inactivation of Tap originated a progressive growth defect and altered 
morphology in M.bovis strains, as well as an alteration in gene expression in stationary 
growth phase, but not during exponential  growth.  
 
Gene regulation in KOTap cells during stationary growth phase: 
Results show that Tap is needed to maintain 
balanced physiological functions during late 
stationary phase and in latency. As bacterial 
growth is arrested during the stationary phase, 
toxic waste products accumulate inside the cell 
and must be cleared from the cytoplasm; so, toxics 
are substrates of Tap when nutrients are limited. 
This explains the upregulation of genes involved in 
general stress responses, acting as a detoxifying 
system. [3] 
To determine if the resistance to INH was due to 
MmpL7 as active drug efflux mechanism, the 
accumulation of this drug was monitored in 
M.smegmatis cells carrying either pSODIT/mmpL7  
and pSODIT-2 shuttle vectors  from M.tuberculosis. 
 
 Strains were incubated with INH, and its 
intracellular concentration was measured at various 
time points. Cells harboring pSODIT-2 had a low 
level drug accumulation. 
Consequently, the M. tuberculosis MmpL7 protein can utilize INH as a substrate when it is 
expressed in M. segmantis, while M. tuberculosis INH could compete with the natural 
substrate (PDIM) of MmpL7 since its principal physiological role appears to be the export of 
complex lipids to the cell exterior. Its overexpression also confers low-level INH resistance. 
Results suggest that MmpL7 is an efflux pump responsible for the INH resistance in an 
energy dependent process. [7] 
 
In general, increased activity of efflux systems is responsible for conferring low-level resistance 
to antibiotics, contrasting with the high-level resistance caused by mutations in gene  
encoding for the primary targets of these antibiotics.   
 
 
In the pathogen Mycobacterium tuberculosis, drug resistance is mainly due to chromosomal mutations in genes encoding the drug target or 
prodrug activating enzymes. However, drug efflux pumps could contribute to the acquisition of such mutations  and explains why mutations in 
the target genes were not found in many low level resistant strains.  Some efflux pumps have been characterized to know whether they are 
involved on MDR-TB and the role they play. These pumps are Tap and MmpL7 for extrusion of rifampicin and a isoniazid, respectively. [2] 
 
The objective of this study is to have an idea if the efflux pumps have an important role in MDR-TB and to see their 
inhibitors as a new possible therapies. 
• Upregulated genes: stress response genes and genes encoding for peptidglican components. 
• Downregulated genes:  Mainly genes of cell wall processing. 
During TB treatment periods, exposure of a rifampicin-resistant strain to rifampicin 
stimulates cross-resistance, inducing resistance to ofloxacin, one of the most effective 
second-line anti-TB drugs, as they both are recognized by the same pump. [5] 
 
INTRODUCTION 
 
A Tap inhibitor could provide new strategies for TB therapy, allowing shortened 
treatment, but their use for TB therapy generates concerns about the pharmacological 
effects on cardiac conduction and  disorders associated with Ca2+  channel blockers.[4] 
 
To determine the effect of membrane deenergization on the uptake of INH, reserpine was 
added to cells containing INH. Then, to test if the available source of energy could lead to 
drug efflux, glycerol was added 15 min after the addition of reserpine.  
 
  
 
Efflux pump inhibitors: reserpine, CCCP and verapamil 
 
•The analysis of genome sequences have shown that M. tuberculosis has many open reading frames of putative efflux pumps. However, the role of these pumps in intrinsic and acquired resistance 
has not been  determined as a major cause of the antibiotic resistance of mycobacteria. They are responsible for low-level resistance. 
•One efflux pump is able to confer resistance to two antibiotics for  its ability to recognize both as substrates. Further, it presents cross-resistance developing MDR, which alters not only first-line 
drugs, but also second-line anti-TB drugs. This makes the treatment period longer and more difficult. 
•More research is needed, either for efflux pumps, because not all of them have been characterized, or for their inhibitors, because the known ones  lead to pharmacological disorders. 
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Figure 1:  Characteristics of Mmpl7 and Tap efflux pumps. 
Figure 2:  M.Bovis BCG gene regulation during stationary growth 
phase when exposed to INH. 
. Figures 6 and 7 show the effects of  efflux pump inhibitos to different strains. In Figure 7  is  also represented the addition of 
glycerol 15 min after the addition of reserpine.  M.segmantis expressing MmpL7, rapidly eliminated INH 
Figure 6 Figure 7 
Figure 3:  Effects of piperine to different strains of M.tuberculosis 
Drug-tolerant bacteria are originated 
in macrophages dependent on the 
activity of bacterial efflux pumps [6]. 
 
The association between drug 
tolerance and intra-macrophage 
growth suggests that a common 
mechanism promotes both. 
Figure 4:  Macrophage engulfing M.tuberculosis. 
Figure 5:  RND Efflux pump 
 
 
 
 
 
Efflux pump inhibitors: CCP, verapamil and piperine 
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